2019 Analytical Chemistry Licensing Trials 
Drug Discovery World
MARCH 7, 2023
She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. In 2023, the company revealed data from a Phase III trial which showed that its vaccine candidate DCVax-L more than doubled overall survival in glioblastoma patients.
The Pharma Data
NOVEMBER 5, 2020
Prior to joining Imperative Care in 2019, Davis served as chief commercial officer and president of North America at Penumbra, Inc., Prior to this, he held a position as a director of Analytical Chemistry in Drug Discovery at GlaxoSmithKline. Most recently, Holland served as Global Head of licensing at Lonza AG.
Expert insights. Personalized for you.
246 
Let's personalize your content